Updates are available Correction dated 2021-02-24
Click to view Correction: https://doi.org/10.1186/s13058-021-01405-y
-
Authors
Aine, Mattias
Boyaci, Ceren
Hartman, Johan
Häkkinen, Jari
Mitra, Shamik
Campos, Ana Bosch
Nimeus, Emma
Ehinger, Anna
Vallon-Christersson, Johan
Borg, Åke
Staaf, Johan http://orcid.org/0000-0001-5254-5115
-
Funding
Funding for this research was provided by:
Cancerfonden (CAN 2018/685)
Fru Berta Kamprads Stiftelse (2020-5-282)
Lund University
- License Information
-
More Information
Article History
Received: 19 October 2020
Accepted: 11 January 2021
First Online: 10 February 2021
Change Date: 24 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13058-021-01405-y
Ethics approval and consent to participate
: All included patients were enrolled in the Sweden Cancerome Analysis Network – Breast (SCAN-B) study (ExternalRef removed ID NCT02306096) [CitationRef removed–CitationRef removed], approved by the Regional Ethical Review Board in Lund, Sweden (Registration numbers 2009/658, 2010/383, 2012/58, 2016/742, 2018/267 and 2019/01252) as previously described [CitationRef removed]. All patients provided written informed consent prior to enrolment. All analyses were performed in accordance with local and international regulations for research ethics in human subject research.
: Not applicable.
: The authors declare that they have no competing interests with exception of Johan Hartman who has received speakers’ honoraria and travel support from Roche, advisory board fees from MSD, Novartis, and Roche, and institutional research grants from Cepheid and Novartis, and is the co-founder and shareholder of Stratipath AB.
